Cargando…

Design of the Optimal Trial of Combination Therapy

Patients who take levothyroxine monotherapy to treat hypothyroidism frequently experience residual symptoms despite TSH testing at target levels. Trials have been conducted to evaluate the potential benefit of combination therapy with levothyroxine and liothyronine, though results have not consisten...

Descripción completa

Detalles Bibliográficos
Autor principal: Cappola, Anne R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146056/
https://www.ncbi.nlm.nih.gov/pubmed/32318021
http://dx.doi.org/10.3389/fendo.2020.00168
_version_ 1783520112647602176
author Cappola, Anne R.
author_facet Cappola, Anne R.
author_sort Cappola, Anne R.
collection PubMed
description Patients who take levothyroxine monotherapy to treat hypothyroidism frequently experience residual symptoms despite TSH testing at target levels. Trials have been conducted to evaluate the potential benefit of combination therapy with levothyroxine and liothyronine, though results have not consistently demonstrated benefit. In addition to randomization, placebo-control, and masking, four additional design choices to consider include the study population, dosing strategy for levothyroxine and liothyronine, primary and secondary outcome selection, and statistical power. A thoughtful design that considers these features will increase the likelihood that a combination trial will be considered definitive and finally resolve the important question of whether combination therapy with levothyroxine and liothyronine is a better thyroid replacement strategy than levothyroxine monotherapy.
format Online
Article
Text
id pubmed-7146056
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-71460562020-04-21 Design of the Optimal Trial of Combination Therapy Cappola, Anne R. Front Endocrinol (Lausanne) Endocrinology Patients who take levothyroxine monotherapy to treat hypothyroidism frequently experience residual symptoms despite TSH testing at target levels. Trials have been conducted to evaluate the potential benefit of combination therapy with levothyroxine and liothyronine, though results have not consistently demonstrated benefit. In addition to randomization, placebo-control, and masking, four additional design choices to consider include the study population, dosing strategy for levothyroxine and liothyronine, primary and secondary outcome selection, and statistical power. A thoughtful design that considers these features will increase the likelihood that a combination trial will be considered definitive and finally resolve the important question of whether combination therapy with levothyroxine and liothyronine is a better thyroid replacement strategy than levothyroxine monotherapy. Frontiers Media S.A. 2020-04-03 /pmc/articles/PMC7146056/ /pubmed/32318021 http://dx.doi.org/10.3389/fendo.2020.00168 Text en Copyright © 2020 Cappola. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Cappola, Anne R.
Design of the Optimal Trial of Combination Therapy
title Design of the Optimal Trial of Combination Therapy
title_full Design of the Optimal Trial of Combination Therapy
title_fullStr Design of the Optimal Trial of Combination Therapy
title_full_unstemmed Design of the Optimal Trial of Combination Therapy
title_short Design of the Optimal Trial of Combination Therapy
title_sort design of the optimal trial of combination therapy
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146056/
https://www.ncbi.nlm.nih.gov/pubmed/32318021
http://dx.doi.org/10.3389/fendo.2020.00168
work_keys_str_mv AT cappolaanner designoftheoptimaltrialofcombinationtherapy